Healthcare economist experts working on the Blue Cross Blue Shield antitrust case for the past decade have calculated a value for the settlement’s injunctive relief in excess of $17.3 billion over the first ten years of its implementation. In addition to a $2.8 billion monetary payment, the significant benefits of the settlement’s injunctive relief include specific commitments relating to transparency, efficiency, and Blue Plan accountability that will directly benefit providers and the patients they serve.